People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Healthtech, Other, Other Technology, Pharma, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Upfront Healthcare Services, Inc. | — | Healthtech | Series C | $94.1M | $34.5M | 2020 |
| Hireology, Inc. | — | Other | Series A | $43.9M | $181.6M | 2016 |
| Focus IP, Inc. | — | Other Technology | Series A | $35.0M | $4.9M | 2023 |
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2024 |
| Forj Software, Inc. | — | Software / Tech | Series B | $28.1M | $12.9M | 2026 |
| Montage Talent, Inc. | — | Other Technology | Series A | $15.6M | $228.4M | 2017 |
| Catalyze, Inc. | — | Other Technology | Series A | $12.5M | $179.3M | 2016 |
| Vodori, Inc. | — | Other Technology | Series A | $11.7M | $127.0M | 2021 |
| Coalfire Systems, Inc. | — | Other Technology | Series A | $9.3M | $98.5M | 2013 |
James Pavlik at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Pavlik on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Schleicher | 2 | 7 |
| Kurt Heikkinen | 2 | 4 |
| Mark Bakken | 1 | 24 |
| Brian Smith | 1 | 22 |
| Jonathan Phillips | 1 | 14 |
| Brad Keywell | 1 | 12 |
| David Rubin | 1 | 11 |
| NICK EFSTRATIS | 1 | 10 |
| Jeffrey Williams | 1 | 10 |
| Christopher O'Donnell | 1 | 8 |
| Jan Garfinkle | 1 | 7 |
| Michael Krupka | 1 | 7 |
| Robert Coppedge | 1 | 6 |
| Brook Critchfield | 1 | 6 |
| William Blake | 1 | 5 |
| George Mulhern | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| William Burkoth | 1 | 5 |
| Brian Hopcraft | 1 | 5 |
| Justin Dearborn | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.